Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vivimed Labs Limited ( (IN:VIVIMEDLAB) ) has shared an update.
Vivimed Labs Limited’s Board of Directors approved several key resolutions in their recent meeting, including the submission of unaudited financial results for the quarter ending June 30, 2025, and the re-appointment of key directors and auditors. Despite these developments, the company faces financial challenges, with a significant default in loan repayments amounting to Rs 3,748.22 million, leading to all loan accounts being classified as non-performing assets by banks. This financial strain could impact the company’s operational stability and stakeholder confidence.
More about Vivimed Labs Limited
Vivimed Labs Limited operates in the pharmaceutical industry, focusing on the production and distribution of active pharmaceutical ingredients, finished formulations, and specialty chemicals. The company primarily serves the healthcare and personal care markets.
Current Market Cap: 406.3M INR
For a thorough assessment of VIVIMEDLAB stock, go to TipRanks’ Stock Analysis page.